



(51) International Patent Classification:

C08G 69/10 (2006.01) A61P 31/04 (2006.01)
C08G 69/48 (2006.01) A61P 35/00 (2006.01)
A61K 31/785 (2006.01)

(21) International Application Number:

PCT/SG2022/050519

(22) International Filing Date:

22 July 2022 (22.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202108073W 23 July 2021 (23.07.2021) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **YANG, Yi Yan**; c/o Institute of Bioengineering and Bioimaging, 31 Biopolis Way, The Nanos, #07-01, Singapore 138669 (SG). **YANG, Shengcai**; c/o Institute of Bioengineering and Bioimaging, 31 Biopolis Way, The Nanos, #07-01, Singapore 138669 (SG). **TAN, Wei Ping**

Eddy; c/o Institute of Bioengineering and Bioimaging, 31 Biopolis Way, The Nanos, #07-01, Singapore 138669 (SG).

(74) Agent: **DAVIES COLLISON CAVE ASIA PTE. LTD.**; 10 Collyer Quay #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: FUNCTIONALISED POLYPEPTIDES, NANOPARTICLES AND USES THEREOF




Figure 1

(57) Abstract: The present disclosure relates to functionalised polypeptides, nanoparticles and their 5 uses thereof. The functionalised polypeptide comprises polylysine functionalised with guanidinium moieties, wherein the polypeptide is about 50% to about 98% functionalised. The number of guanidinium functionalised lysine monomeric units is 5 to 100, and the number of lysine monomeric units is 1 to 50. The functionalised polypeptides and nanoparticles can be used for treating a microbial infection or for 10 treating cancer.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

23 February 2023 (23.02.2023)